Navigation Links
Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
Date:5/19/2008

SAN DIEGO, May 19 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of therapeutic oxygen transport agents today announced that it has completed enrollment in the second Phase III trial of its lead product, Hemospan(R).

Sangart expects the top line results from this trial to be available in the second half of 2008.

The 370-patient randomized, double-blind, controlled Phase III study was conducted at 18 clinical sites in six European countries. Together with another Phase III study completed in March, the trials were designed to evaluate the safety and efficacy of Hemospan for preventing and treating hemodynamic instability, particularly hypotension, or low blood pressure, during primary hip replacement surgery.

Dr. Robert Winslow, Chairman, President and CEO of Sangart, commented, "The completed enrollment in this second Phase III trial represents another significant milestone for Sangart as we advance the development of Hemospan."

No similar oxygen transport agents are currently on the market in Europe or the United States. Extensive preclinical efficacy studies and earlier clinical trials indicate that Hemospan's novel oxygen delivery mechanism has the potential to enhance oxygenation of ischemic tissues and may provide a safe and effective alternative to blood transfusion, especially when blood is not immediately available.

About Sangart

Sangart is a privately held San Diego-based biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as therapeutic oxygen transport agents and potential alternatives to blood transfusions.

Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-f
'/>"/>

SOURCE Sangart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
2. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
3. China-Biotics, Inc. Completes Foundation for Its New Plant
4. Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
5. EUSA Pharma Completes Acquisition Of Cytogen Corporation
6. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
7. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
8. Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution
9. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
10. Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections
11. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Outlines Ambitious Growth Plans, Technology Leadership, INDIANAPOLIS, ... AgroSciences, a wholly owned subsidiary of The Dow ... of a presentation made to investors,earlier today by ... was speaking at the Goldman Sachs Agricultural Chemicals,Conference ...
... February 12, Shire plc (LSE: SHP)(NASDAQ: SHPGY )(TSX: ... earnings on Thursday 21 February 2008., Results ... 12:00 GMT / 07:00 EST Investor meeting and ... Investor & Analyst meeting and conference call:, ...
... Healthcare Clients Throughout a ... Product,s Lifecycle, NEW ... Maryland-based MMG, an industry leader in patient,enrollment for clinical trials, will ... group. With this partnership, Ketchum,will greatly expand the depth of services ...
Cached Biology Technology:Dow AgroSciences' Success Presented to Wall Street 2Full Year 2007 Results Date Notification - 21 February 2008 2Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG 2Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG 3Ketchum Joins Forces with Clinical Trial Recruitment Agency MMG 4
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)...   News Highlights: ... The Partners Data Lake, an agile data and ... will allow researcher and clinicians to explore and ... lives of patients , The Partners Data ... the Partners system, breaking down physical barriers for ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... Chinese on EurekAlert! Chinese . An ... Vinatzer and Giorgio Balestra of the University of Tuscia in ... a devastating pathogen back to its likely origin. ... ) has been threatening the world,s kiwifruit industry and destroying ...
... natural habitat in farming areas that supports ladybugs could help ... help farmers reduce their costs, says a Michigan State University ... saving farmers an estimated $4.6 billion a year on insecticides. ... helping them to survive and thrive in areas where they ...
... announced today that it is a Grand Challenges Explorations winner, ... Dr. Gregor Reid and his team are the first ... The research project will study the impact of ... on the health outcomes of pregnant women and their children. ...
Cached Biology News:Virginia Tech and University of Tuscia lead team to unravel origin of devastating kiwifruit bacterium 2Virginia Tech and University of Tuscia lead team to unravel origin of devastating kiwifruit bacterium 3Increasing predator-friendly land can help farmers reduce costs 2Lawson recieves Grand Challenges Explorations grant for groundbreaking research 2
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
Homo sapiens jumping translocation breakpoint...
One-step, microplate or cuvet, colorimetric 530nm, detection limit 0.16mg/dL in serum or plasma. Procedure: 10 min....
MOUSE ANTI HUMAN NPM...
Biology Products: